ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Psychedelic Passage and Miraculix Unite to Enhance Safety in Psychedelic Therapy

Denver, Colorado (Newsworthy.ai) Tuesday Apr 23, 2024 @ 7:00 AM Eastern —

Psychedelic Passage, a service that connects clients with their network of pre-vetted psychedelic facilitators, and Miraculix, which specializes in the analysis of psychoactive substances, are collaborating to improve safety in psychedelic therapy by incorporating Miraculix’s scientific expertise and analysis technologies into the client experiences managed by Psychedelic Passage.

Founded in 2019 by Jimmy Nguyen and Nicholas Levich, Psychedelic Passage has transformed access to psychedelic therapy, tailoring each client's journey from preparation to integration, considering over 20 variables like specialty and gender preferences. Their commitment extends to educating the community through resources like blogs, podcasts, and free monthly Q&As.

Miraculix, led by Dr. Felix Blei, Frank Junger, and Roxana Budnik, brings to the partnership a wealth of expertise in natural product analysis and the scientific understanding of psychotropic substances. Their QTest technology delivers precise analysis of psychoactive compound concentrations, crucial for safe psychedelic use and accurate dosage determination.

Miraculix's commitment to empowering individuals through informed decisions complements the mission of Psychedelic Passage, which believes in the fundamental right to explore consciousness using psychedelics in safe, meaningful, and sacred ceremonial settings.

This collaboration introduces an innovative initiative where Psychedelic Passage clients can participate in community research projects led by Miraculix. By using tools like Miraculix’s Psilocybin QTest kits, clients contribute to studies that enhance understanding of psychedelics, such as the entourage effect in psychedelic mushrooms. This not only enriches personal experiences but also adds valuable data to global psychedelic research.

"We're excited about this partnership," said Jimmy Nguyen of Psychedelic Passage. "Incorporating Miraculix's advanced scientific analysis into our services will improve the safety and effectiveness of our client's psychedelic journeys."

Dr. Felix Blei of Miraculix added, "Our collaboration with Psychedelic Passage is a significant step forward in our mission to enhance harm reduction and empower individuals with scientific knowledge. We're eager to bring our research and technology to a wider audience, ensuring safer and better-informed psychedelic use."

To engage with this community research initiative or learn more about the partnership, tune into the latest episode of the Psychedelic Passage podcast featuring Dr. Felix Blei, or visit the Miraculix Community Research page.

About Psychedelic Passage

Psychedelic Passage connects individuals with a nationwide network of pre-vetted psychedelic facilitators. Founded in 2019 by Jimmy Nguyen and Nicholas Levich, the company prioritizes safety, education, and personalized guidance throughout the psychedelic experience, from preparation to integration.

About Miraculix

Miraculix specializes in the scientific analysis and consultation regarding natural psychotropic substances, with a focus on psilocybin. The company’s QTest technology offers accurate, scientifically validated substance analysis, enabling safer use and enhanced understanding of psychoactive materials.

Contact Information:

Psychedelic Passage Media Relations

Email: marketing@psychedelicpassage.com

Miraculix Press Office

Email: info@miraculix-lab.com

This press release is distributed by the Newsworthy.ai™ Press Release Newswire - News Marketing Platform.™

The reference URL for this press release is located here Psychedelic Passage and Miraculix Unite to Enhance Safety in Psychedelic Therapy.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.